Archive — US — techcrunch
Triomics nabs $22M to bring oncology-specific AI to cancer centers
Triomics raised $22M in Series B funding to develop an AI platform for oncology, aiding oncologists in automating data tasks like clinical trial matching, amidst increasing patient record complexities. Founded in 2021, the startup has seen rapid growth, particularly in oncology-specific tools, enhancing patient care efficiency while addressing administrative burdens.
Key points
- Triomics raised $22M in Series B funding led by Battery Ventures.
- The startup helps oncologists automate data-intensive tasks such as clinical trial matching and appointment preparation.
- An increase in oncology breakthroughs has resulted in dense medical records, complicating staff workload.
- Triomics expanded its platform capabilities with AI features to include verifiable patient summaries, improving efficiency.
- The startup's technology is used by top oncology institutions, differentiating from generic AI tools.
- Triomics has expanded its customer base fourfold over the last year and achieved a tenfold increase in annual recurring revenue.
Why it matters
- The rise of AI in healthcare, particularly in oncology, aligns with broader 2025 IT trends focusing on automation and data analysis.
- The increasing complexity of medical records reflects a growing trend in precision medicine and the need for advanced data solutions.
- As healthcare faces staffing shortages, tools that alleviate administrative burdens are increasingly critical, reflecting ongoing needs for efficiency in clinical settings.
Triomics' innovative AI solutions represent a significant advancement in oncology, addressing both patient care and administrative efficiency, indicating a strong growth trajectory in the healthcare tech landscape.